Safety assessment of vitacoxib: Acute and 90‐day sub‐chronic oral toxicity studies
Sign Up to like & getrecommendations! Published in 2017 at "Regulatory Toxicology and Pharmacology"
DOI: 10.1016/j.yrtph.2017.02.020
Abstract: &NA; Vitacoxib, is a newly developed coxibs NSAID (selective inhibitors of cyclooxygenase‐2). To date, no experimental data have been published concerning its safety for use as an additive in the human diet. In the present… read more here.
Keywords: vitacoxib; sub chronic; chronic toxicity; toxicity ... See more keywords
Safety assessment of vitacoxib: 180‐day chronic oral toxicity studies
Sign Up to like & getrecommendations! Published in 2018 at "Regulatory Toxicology and Pharmacology"
DOI: 10.1016/j.yrtph.2018.03.024
Abstract: ABSTRACT Vitacoxib, a selective COX‐2 inhibitor, is approved for the relief of pain and inflammation associated with orthopedic surgery and osteoarthritis in dogs. In the current study, a chronic toxicity research was performed to evaluate… read more here.
Keywords: chronic oral; vitacoxib; 180 day; toxicity ... See more keywords
Pharmacokinetics, Tissue Distribution, Metabolism and Excretion of a Novel COX-2 Inhibitor, Vitacoxib, in Rats
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Veterinary Science"
DOI: 10.3389/fvets.2022.884357
Abstract: The objectives of this study were to elucidate absorption, tissue distribution, excretion, and metabolism of vitacoxib, a novel selective cyclooxygenase-2 inhibitor, in Wistar rats. Vitacoxib was detected in most tissues within 15 min, suggesting that… read more here.
Keywords: excretion; metabolism; tissue distribution; vitacoxib ... See more keywords